Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Accumulated Expenses (2016 - 2025)

CorMedix's Accumulated Expenses history spans 13 years, with the latest figure at $161.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 2379.65% year-over-year to $161.9 million; the TTM value through Dec 2025 reached $161.9 million, up 2379.65%, while the annual FY2025 figure was $161.9 million, 2379.65% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $161.9 million at CorMedix, up from $806506.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $161.9 million in Q4 2025 and bottomed at $806506.0 in Q3 2025.
  • The 5-year median for Accumulated Expenses is $3.2 million (2022), against an average of $13.1 million.
  • The largest YoY upside for Accumulated Expenses was 2379.65% in 2025 against a maximum downside of 83.16% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $3.0 million in 2021, then decreased by 27.66% to $2.2 million in 2022, then skyrocketed by 135.64% to $5.1 million in 2023, then increased by 27.09% to $6.5 million in 2024, then skyrocketed by 2379.65% to $161.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Accumulated Expenses are $161.9 million (Q4 2025), $806506.0 (Q3 2025), and $25.7 million (Q2 2025).